Computational chemistry

Daewoong Pharmaceutical and Sygnature Discovery announce drug discovery research collaboration

Retrieved on: 
Tuesday, April 18, 2023
Informatics, VHT, Drug development, Drug discovery, Research, HTS, Computational chemistry, Computer, Patent, DMPK, Egypt's Ten Greatest Discoveries, Invention, Crystallography, Biology, PPI, Atomic mass, III, Pharmaceutical industry, Fine chemical, Daewoong Pharmaceutical

SEOUL, South Korea and NOTTINGHAM, England, April 18, 2023 /PRNewswire/ -- Daewoong Pharmaceutical has entered a research collaboration with Sygnature Discovery to expand its global open innovation for novel drug development.

Key Points: 
  • On the 18th April, Daewoong Pharmaceutical (CEO Seng-ho Jeon and Lee Chang-jae) has announced a research collaboration with Sygnature Discovery (CEO Simon Hirst), a global integrated drug discovery company, to discover a novel small molecule to target autoimmune diseases.
  • Sygnature Discovery will provide its proprietary Fragment-Based Drug Discovery (FBDD) and virtual high throughput screening (vHTS) to accelerate Daewoong's novel drug discovery for autoimmune diseases.
  • Through this collaboration, Daewoong Pharmaceutical expects to broaden its drug discovery scope to the field of protein-protein interaction (PPI) as a part of next-generation drug discovery strategy.
  • Sygnature Discovery is an integrated drug discovery company established in 2004 to support early drug development and clinical trials.

TANAKA Memorial Foundation Announces Recipients of Precious Metals Research Grants

Retrieved on: 
Friday, March 31, 2023
Money, Asian Young Researchers Conference on Computational and Omics Biology, Gold Award (Girl Scouts of the USA), Ruthenium, Nagoya Institute of Technology, University, Silver, Osmium, Platinum, Research, Computational chemistry, Orientation, Palladium, Associate, Marketing, Science, Osaka University, Silver Award (Girl Scouts of the USA), Gold, Gold Awards, Gold Award, Iridium, Hokkaido University, Global marketing, Rhodium, Alloy, Pharmaceutical industry, Nursing, Rudolf Mössbauer

TOKYO, Mar 31, 2023 - (JCN Newswire) - The TANAKA Memorial Foundation's Representative Director, Hideya Okamoto, announced the recipients of the FY2022 Precious Metals Research Grants.

Key Points: 
  • TOKYO, Mar 31, 2023 - (JCN Newswire) - The TANAKA Memorial Foundation's Representative Director, Hideya Okamoto, announced the recipients of the FY2022 Precious Metals Research Grants.
  • The recipients and an overview of the Precious Metals Research Grants are indicated below.
  • Purpose of Business: To provide grants for research related to precious metals to contribute to the development and cultivation of new fields for precious metals, and to the development of science, technology, and the social economy.
  • - Provision of grants for scientific and technological research related to precious metals.

TandemAI Announces the Release of TandemViz™ 1.0 Web-based Graphical User Interface for Seamless Integration of Computational Analyses and Experimental Data

Retrieved on: 
Tuesday, March 28, 2023
Data Management, Health, Technology, Mobile, Wireless, Pharmaceutical, Biotechnology, Drug discovery, Amgen, Entrepreneurship, Lead, Data analysis, Web browser, FEP, Computational chemistry, Workflow, Video game, Fine chemical

TandemAI today announced the release of TandemViz™ 1.0, the company’s proprietary web-based platform that provides its growing roster of drug discovery clients with a user-friendly and collaborative graphical interface to TandemAI’s suite of computational tools.

Key Points: 
  • TandemAI today announced the release of TandemViz™ 1.0, the company’s proprietary web-based platform that provides its growing roster of drug discovery clients with a user-friendly and collaborative graphical interface to TandemAI’s suite of computational tools.
  • The platform, which can be accessed from anywhere through a web browser without the need to install any software locally, allows the seamless integration and visualization of experimental data alongside computational analyses.
  • “TandemViz is central to our approach to integrating advanced computational tools with wet lab technologies,” said Albert Pan, Ph.D., TandemAI’s Chief Technology Officer.
  • Additional features, including tools for generative design and billion-level virtual high throughput screening, will be available soon in future versions of TandemViz.

Meliora Therapeutics Appoints Claudio Chuaqui, Ph.D., as Head of Drug Discovery

Retrieved on: 
Monday, March 27, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Drug development, University, Drug discovery, Computational chemistry, AstraZeneca, Publication, Biology, Physics, Meliora, Research, FDA, SVP, Therapy, University of Manitoba, Pharmaceutical industry, Biogen, Chemistry

Meliora Therapeutics , a biotech company pioneering a machine learning-driven approach to mechanism driven oncology drug development, announced the appointment of Claudio Chuaqui, Ph.D, as Senior Vice President (SVP), Head of Drug Discovery.

Key Points: 
  • Meliora Therapeutics , a biotech company pioneering a machine learning-driven approach to mechanism driven oncology drug development, announced the appointment of Claudio Chuaqui, Ph.D, as Senior Vice President (SVP), Head of Drug Discovery.
  • Dr. Chuaqui will lead the drug discovery group which includes biology, medicinal chemistry, biochemistry/biophysics, and computational chemistry.
  • Dr. Chuaqui brings more than 20 years of drug discovery experience to Meliora Therapeutics.
  • Meliora is bringing the latest genomic, computational, and machine learning techniques to change the current paradigm of oncology drug discovery,” said Claudio Chuaqui, Ph.D, SVP, Head of Drug Discovery.

Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders

Retrieved on: 
Wednesday, March 22, 2023
Computational biology, Software engineering, Hsp90, Partnership, University, Doctor of Philosophy, Drug discovery, Oppenheimer, ARCH Venture Partners, Computational science, Health, ICREA, ML, Autonomous University of Barcelona, Drug design, Computational chemistry, Chemistry, University of Barcelona, MCA, The Co Founder, Novartis, Machine learning, University of Washington Information School, Engineering, Vernalis, Artificial intelligence, Biology, AI, Research, Therapy, VC, Data science, Pharmaceutical industry, Medical device, Biochemistry, Numeracy, Physics

The fireside chat, titled “Computational Biology in Drug Discovery with Gain Therapeutics (GANX) CTO & Two Experts,” will take place on Wednesday, March 29, 2023 at 12:00 pm ET.

Key Points: 
  • The fireside chat, titled “Computational Biology in Drug Discovery with Gain Therapeutics (GANX) CTO & Two Experts,” will take place on Wednesday, March 29, 2023 at 12:00 pm ET.
  • He is an entrepreneur focused on applying machine learning (ML) and large scale computational methods to improve human health.
  • Prior to Valo Health, Brandon was the co-founder and Chief Technology Officer of Numerate, a leader in ML-driven computational small molecule drug design.
  • Dr. Barril has over 18 years of experience in computational chemistry and drug discovery.

Ajax Therapeutics Appoints Alan Collis, PhD, as Senior Vice President and Head of Preclinical Development

Retrieved on: 
Thursday, March 9, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Computational chemistry, JAK2, DMPK, Chemistry, BET, IND, Novartis Institute for Tropical Diseases, Novartis, Nimbus, University, Pancreatic serous cystadenoma, Biocon, IDH1, Forma, Therapy, Biomedical Research, Patient, JAK, Disease, Drug development, Preclinical development, Ajax, Doctor of Philosophy, TYK2, Sanofi, MPN, Senior, Pharmaceutical industry, Safety

Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop next generation JAK inhibitors for myeloproliferative neoplasms (MPNs), today announced the appointment of Alan Collis, PhD, as Senior Vice President and Head of Preclinical Development.

Key Points: 
  • Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop next generation JAK inhibitors for myeloproliferative neoplasms (MPNs), today announced the appointment of Alan Collis, PhD, as Senior Vice President and Head of Preclinical Development.
  • Dr. Collis brings over 25 years of drug development experience to Ajax with previous preclinical development roles at Novartis, Forma Therapeutics and Nimbus Therapeutics.
  • “We are excited to have Alan join Ajax as we transition our lead Type II JAK2 inhibitor program into IND enabling studies,” said Martin Vogelbaum, CEO of Ajax Therapeutics.
  • Prior to Syngene, he served as Senior Vice President of Preclinical Development at Nimbus Therapeutics where led the preclinical and IND activities for the company’s TYK2 and HPK-1 inhibitor programs.

Comstock Expands Leadership for Li-Ion Battery Recycling

Retrieved on: 
Thursday, March 2, 2023
Paragon, NYSE, Doctor of Philosophy, MBA, Master of Science, SC, Gray Court, South Carolina, Smithfield Foods, Engineering, Louisiana Army Ammunition Plant, Grays Court, York, Metal, JV, Knowledge, UTEC, Computational chemistry, ISCB Senior Scientist Award, Indiana Army Ammunition Plant, Atlas Powder Company, Analytical chemistry, Apollo Global Management, Atlas, DCS, R, ICI, Medical device, Chemistry

VIRGINIA CITY, Nev., March 02, 2023 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock” or the “Company”) today announced the appointment of Dr. Fortunato Villamagna as the President of Comstock Metals Corporation, the entity that owns LINICO Corporation, the Company’s Li-Ion battery metals recycling business.

Key Points: 
  • VIRGINIA CITY, Nev., March 02, 2023 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock” or the “Company”) today announced the appointment of Dr. Fortunato Villamagna as the President of Comstock Metals Corporation, the entity that owns LINICO Corporation, the Company’s Li-Ion battery metals recycling business.
  • Mr. Corrado De Gasperis, Executive Chairman and CEO, said, “We are honored to welcome Dr. Villamagna to our battery metals team.
  • Dr. Villamagna also owns and operates i-Quest Inc., a technology company focused on metal recycling that will amalgamate with Comstock Metals Corporation.
  • Mr. De Gasperis concluded, “Fortunato will be instrumental in deploying our pilot, producing black mass and battery metals, expanding our operations and supply chain, and advancing our technology leadership in Nevada.”

Schrödinger Reports Strong Fourth Quarter and Full-Year 2022 Financial Results

Retrieved on: 
Tuesday, February 28, 2023
Health, Technology, Software, General Health, Pharmaceutical, Biotechnology, History of the University of Maryland, College Park, Safety, Therapy, Computational chemistry, University, LRRK2, Psoriasis, Mathematics, IND, Acquisition, Drug discovery, Research, Engineering, Outline of physical science, Neurology, Patient, KPI-driven code analysis, CNS, College Park, Polymer, MALT1, Faculty, Materials science, Lymphoid leukemia, AbbVie, Machine learning, Biochemistry, TYK2, Biophysics, Bristol Myers Squibb, Hair, CDC7, Society, Pharmacokinetics, Pharmaceutical industry, Nimbus, IPO

NDI-034858 is being evaluated for the treatment of multiple autoimmune diseases following positive Phase 2b results in psoriasis.

Key Points: 
  • NDI-034858 is being evaluated for the treatment of multiple autoimmune diseases following positive Phase 2b results in psoriasis.
  • The distribution was on account of Schrödinger’s equity stake in Nimbus, which as of December 31, 2022, was 3.8% on a fully diluted basis.
  • Schrödinger participated in the IPO and now holds a 3.7 percent equity stake in Structure Therapeutics.
  • Schrödinger will host a conference call to discuss its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, at 4:30 p.m.

Nimbus Therapeutics Announces Closing of Takeda’s Acquisition of TYK2 Subsidiary

Retrieved on: 
Wednesday, February 8, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, MBA, TYK2, Therapy, HPK1, Acquisition, Patient, Computational chemistry, Psoriasis Area and Severity Index, TAK, DSM-IV codes, Psoriasis, Cancer, Pharmaceutical industry, Nimbus, Takeda

Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced the closing of Takeda’s (TSE:4502/NYSE:TAK) acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 (TYK2) inhibitor program, which includes the oral, selective allosteric TYK2 inhibitor NDI-034858, now known as TAK-279.

Key Points: 
  • Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced the closing of Takeda’s (TSE:4502/NYSE:TAK) acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 (TYK2) inhibitor program, which includes the oral, selective allosteric TYK2 inhibitor NDI-034858, now known as TAK-279.
  • The completion of this acquisition triggered a $4 billion upfront payment from Takeda to Nimbus, which is also eligible to receive up to $2 billion total in sales-based milestone payments.
  • Nimbus previously announced that NDI-034858 achieved the trial’s primary efficacy endpoint, with a statistically significant greater proportion of patients reaching PASI-75 (a 75% improvement in skin lesions as measured by the Psoriasis Area and Severity Index) compared to placebo at 12 weeks.
  • Nimbus retains ownership of and continues to advance a portfolio of potentially transformative therapeutics for cancer, autoimmune diseases and metabolic disorders, including NDI-101150, a selective hematopoietic progenitor kinase 1 (HPK1) inhibitor, currently being evaluated in a Phase 1/2 study in patients with solid tumors.

ValGenesis and Scignyte Partner to Deliver One-Stop Digital Transformation Solutions for Scientific Research and Development Organizations across Asia

Retrieved on: 
Tuesday, February 7, 2023
Computational chemistry, Organization, D, Data mining, Vaccine, Acceleration, Biology, Market research, Canadian industrial research and development organizations, Risk, Scientific method, Partnership, SAN, Conceptual model, Risk management, Medical device

SAN FRANCISCO, Feb. 7, 2023 /PRNewswire/ -- ValGenesis, Inc., the market leader in enterprise Validation Lifecycle Management Systems (VLMS), and Scignyte, an innovative technology company, have partnered to deliver one-stop digital validation solutions for Scientific Research and Development Organizations across Asia.

Key Points: 
  • SAN FRANCISCO, Feb. 7, 2023 /PRNewswire/ -- ValGenesis, Inc., the market leader in enterprise Validation Lifecycle Management Systems (VLMS), and Scignyte, an innovative technology company, have partnered to deliver one-stop digital validation solutions for Scientific Research and Development Organizations across Asia.
  • As part of the partnership, Scignyte will implement and manage next generation digital validation tools developed by ValGenesis for R&D organizations.
  • "This partnership allows us to serve scientific research and development organizations across Asia through next generation digital validation tools that efficiently mitigate risk and enforce compliance," says Bo Olsen, ValGenesis' SVP of Partners.
  • "We are thrilled to partner with Scignyte to offer combined solutions to this region, pursuing our vision of empowering more R&D organizations to achieve their digital validation goals," he stated.